Standard BioTools Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2025-04-30: Measure Total revenue.
- 2025-04-30: Measure Cost synergies.
- 2025-04-30: Measure Gross margin expansion.
- 2026-04-27: Measure Total revenue.
| Proxy filed | Measure |
|---|---|
| 2025-04-30 | Total revenue |
| 2025-04-30 | Cost synergies |
| 2025-04-30 | Gross margin expansion |
| 2026-04-27 | Total revenue |
| 2026-04-27 | Cost synergies |
| 2026-04-27 | Gross margin expansion |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |